 subjects
with peripheral arterial disease. Vasc Med 2001;6:31-4.
103. American College of Sports Medicine Position Stand and American
Heart Association. Recommendations for cardiovascular screening,
stafﬁng, and emergency policies at health/ﬁtness facilities. Med Sci
Sports Exerc 1998;30:1009-18.
104. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipidlowering for peripheral arterial disease of the lower limb. Cochrane
Database Syst Rev 2007;(4):CD000123.
105. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP,
Hemmingsen C, et al. Targeting intensive glycaemic control versus
targeting conventional glycaemic control for type 2 diabetes mellitus.
Cochrane Database Syst Rev 2013;11:CD008143.
106. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst
Rev 2011;(11):CD001272.
107. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S,
et al. Systematic review of the efﬁcacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
Br J Surg 2012;99:1630-8.
108. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the
treatment of claudication pain. A meta-analysis. JAMA 1995;274:
975-80.
109. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of
treadmill walking exercise versus strength training for patients with
peripheral arterial disease. Implications for the mechanism of the
training response. Circulation 1994;90:1866-74.
